Laboratory News and Research

RSS

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

MicroPhage announced today that it has obtained its CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage Amplification technology.

8 Dec 2009

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Calling his work "one of the most important findings in breast cancer and health disparities in the last decade," the American Association for Cancer Research (AACR) has named Charles M. Perou, Ph.D. the 2009 Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure-.

8 Dec 2009

Roche Diagnostics launches new customer training center in Pleasanton, California

Roche Diagnostics announced today the opening of a new west-coast customer training center in Pleasanton, California, as part of an initiative to make state-of-the-art training on diagnostic equipment more accessible to hospitals and independent laboratories on the west and east coasts.

From Roche Sequencing and Life Science 8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

NeoStem, Inc., which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that an abstract authored by NeoStem-affiliated scientists was presented in a poster presentation at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans on December 5, 2009.

8 Dec 2009

Data shows strong inverse association between coffee consumption and advanced prostate cancer

While it is too early for physicians to start advising their male patients to take up the habit of regular coffee drinking, data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference revealed a strong inverse association between coffee consumption and the risk of lethal and advanced prostate cancers.

8 Dec 2009

New pharmacology textbook released by Elsevier

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the early success and rapid acceptance of its recently released Pharmacology and Therapeutics: Principles to Practice, an innovative new pharmacology textbook designed to better meet the needs of today's residents and practitioners.

8 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

People who drink may want to know that coffee won't sober them up, according to new laboratory research. Instead, a cup of coffee may make it harder for people to realize they're drunk.

8 Dec 2009

CompuCyte expands iGeneration line of imaging cytometers to include four-laser versions

CompuCyte Corporation, the pioneer in the field of imaging cytometry instrumentation and the leading supplier of laser scanning cytometers, announced that it has expanded its state-of-the art iGeneration line of imaging cytometers to include four-laser versions of the iCyte®, iCys® and iColor® systems.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

7 Dec 2009

Cytometry system to precisely control cell movement using sound waves

Applied Biosystems, part of Life Technologies Corporation today announced its entry into the flow cytometry instrumentation market with the debut of the Attune™ Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Interleukin Genetics' PST genetic test approved for marketing in New York

Interleukin Genetics, Inc. announced today it has received approval by the State of New York's Department of Health for the Company to sell in New York its PST Genetic Test that determines predisposition to severe periodontal disease in individuals.

7 Dec 2009

Sustainable development: A critical factor against rising global population and climate change

Sustainability is the only way forward for industry that does not lead to an environmental dead-end. Waste recycling has its place, but researchers in France suggest that from the outset the design of a product should consider the whole life cycle to offer any chance of sustainability.

7 Dec 2009

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.

7 Dec 2009

Micromedex 2.0, the new version of clinical information system to be released

Thomson Reuters today announced the release of Micromedex 2.0, the newest version of its market-leading clinical information system.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies -- according to a presentation at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

Laboratory News and Research

MicroPhage obtains CE mark to market MRSA/MSSA Blood Culture Test in Europe

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Roche Diagnostics launches new customer training center in Pleasanton, California

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

Abstracts on very small embryonic-like stem cells presented at ASH annual meeting

Data shows strong inverse association between coffee consumption and advanced prostate cancer

New pharmacology textbook released by Elsevier

BD Diagnostics receives FDA clearance on Amplified DNA Assays

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

CompuCyte expands iGeneration line of imaging cytometers to include four-laser versions

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Synta Pharmaceuticals announces study results of elesclomol

Cytometry system to precisely control cell movement using sound waves

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Interleukin Genetics' PST genetic test approved for marketing in New York

Sustainable development: A critical factor against rising global population and climate change

ICON, CMFT collaborate to develop translational medicine facilities on the MRI campus

Micromedex 2.0, the new version of clinical information system to be released

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo